Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).
Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).
Correlative findings from the phase 2 ZUMA-2 trial demonstrated that the pharmacokinetic and pharmacodynamic profiles of KTE-X19 were generally comparable across lower and high-risk patients, leading to similar clinical responses. Additionally, the data showed that cytokines can predict the depth of response and neurologic toxicity of the therapy, says Wang. For example, 83% of patients achieved minimal residual disease (MRD) negativity 1 month after receiving KTE-X19. These patients had increased median cytokine levels of interferon (INF)-γ, interleukin (IL)-6, IL-15, IL-2, and IL-10. The serum levels peaked within 7 days of treatment.
Moreover, 6 patients developed grade 4 neurologic events, including 1 case of cerebral edema. Three of these patients developed concurrent grade 4 cytokine release syndrome. Notably, this subgroup of patients had higher peak serum levels of INF-γ, tumor necrosis factor alpha, monocyte chemoattractant protein-1, IL-2 and IL-6 than patients without any grade 4 neurologic events.